Navigation Links
Targanta Therapeutics Announces Pricing of its Initial Public Offering
Date:10/10/2007

CAMBRIDGE, Mass., Oct. 10 /PRNewswire-FirstCall/ -- Targanta Therapeutics Corporation (Nasdaq: TARG) today announced the pricing of its initial public offering of 5,750,000 shares of its common stock at a price to the public of $10.00 per share. All of the shares are being offered by Targanta. Targanta has granted to the underwriters a 30-day option to purchase up to an additional 862,500 shares of common stock at the initial offering price, less underwriting discounts and commissions, to cover over-allotments, if any. Targanta's common stock is scheduled to commence trading on The Nasdaq Global Market on October 10, 2007 under the symbol "TARG."

Credit Suisse is acting as the sole book-running manager for the offering. Cowen and Company, Lazard Capital Markets, and Leerink Swann are acting as co- managers.

Copies of the final prospectus relating to this offering may be obtained from Credit Suisse, Prospectus Department, One Madison Avenue, Level 1B, New York, NY 10010 (telephone number: (212) 325-2580).

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 9, 2007. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Targanta Therapeutics

Targanta Therapeutics Corporation is a biopharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings.


'/>"/>
SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017  Market Research Future has a half cooked research ... Biopsy is growing rapidly and expected to reach USD 450 Million ... ... Biopsy Market has been assessed as a swiftly growing market and ... in the coming future. There has been a tremendous growth in ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... for pharmaceutical research and development (R&D), today announced the launch of ... and interpretation for the rapidly evolving field of precision medicine. , ...
(Date:1/19/2017)... AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), ... and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... listing of its common shares on the NASDAQ Stock ... "AquaBounty,s listing on NASDAQ represents an important milestone ... the U.S. markets as we advance plans for commercial ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... drug and device development, and Prism Clinical Research , a leader in ... Verified Clinical Trials (VCT) has been selected by both companies as ...
Breaking Biology Technology:
(Date:1/12/2017)... NEW YORK , Jan. 12, 2017  New research ... around the office of the future.  1,000 participants were simply ... last three months which we may consider standard issue.  Insights ... office of 2017 were also gathered from futurists and industry ... and Dr. James Canton .  Some ...
(Date:1/6/2017)... Calif. , Jan. 6, 2017  Privately-held ... safety studies in healthy volunteers of a novel ... to treat acute pancreatitis. Acute ... typically a mild disorder, but can be very ... failure and sepsis, where extended hospital stays, time ...
(Date:1/4/2017)... 4, 2017  CES 2017 – Valencell , ... today announced the launch of two new versions ... highly-accurate biometric sensor modules that incorporate the best ... and expertise. The two new designs include Benchmark ... hearables, and Benchmark BW2.0, a 2-LED version of ...
Breaking Biology News(10 mins):